Completed Studies with Published Results
This page features extramurally funded clinical trials supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) that are complete and have published results. Click on a disease/condition below to learn more about a range of clinical trials that NIAMS supported and how they contributed to generating new knowledge about prevention and treatment of arthritis, musculoskeletal and skin diseases. Please note that this page does not include the full portfolio of completed trials with results supported by the NIAMS. Studies with results that completed as of May 2019 are added to this page.
Please check other clinical trials supported by the NIAMS that are actively recruiting or have completed recruitment following the links below.
View Actively Recruiting Studies
View Active Studies with Completed Recruitment
For questions, please contact the NIAMS Clinical Trials team at: NIAMSclinicaltrials@mail.nih.gov
Disease / Condition
Hip fractures occur in 280,000 Americans, over 5,000 per week. During the next 40 years, the number of hip fractures is likely to exceed 500,000 annually, and the estimated annual health care costs will reach a staggering $9.8 billion. Hip fracture patients are at risk of a 30% mortality rate and impairment of independence and quality of life. Hip fractures are commonly treated with a hip replacement, or arthroplasty. Two common types of arthroplasty exist, total hip arthroplasty (THA) and hemi-arthroplasty (HA). Advocates of hemi-arthroplasty (HA) focus upon reduced dislocation rates, lower rates of deep vein thrombosis, shorter operating times, less blood loss, and a technically less demanding procedure. Surgeons supporting THA perceive benefits in improving patient function and improving quality of life. Methodological limitations of previous studies, as well as their small sample sizes and resulting wide confidence intervals, have left the optimal operative approach unresolved.